US equities |
GOOGL $283.39 ▼-12.77% GOOG $281.71 ▼-12.48% MSFT $530.40 ▼-0.11% META $624.97 ▲+2.04% MU $934.13 ▼-4.99% AMZN $243.73 ▼-4.27% NVDA $213.43 ▼-0.91% AAPL $348.91 ▲+1.48%
FinancialContent

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.645 +0.015 (+0.23%)
Delayed Quote Updated: 3:58 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
News headline image
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Where Myriad Genetics Stands With Analysts ↗
 
Via Benzinga
News headline image
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore® 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Myriad Genetics's Future ↗
 
Via Benzinga
News headline image
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year Running 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results ↗
 
Via Benzinga
News headline image
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
Management will also participate in two upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by Myriad 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Myriad Genetics to Host Investor Event on October 9, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >